| |
Johnson & Johnson COVID-19 Vaccine Induces Strong T-Cell Response To Variants
New Evidence Suggests COVID-19 Vaccines Remain Effective Against Variants
|
| |
| |
Download the PDF here
https://www.npr.org/sections/health-shots/2021/06/09/1004738276/new-evidence-suggests-covid-19-vaccines-remain-effective-against-variants
June 9, 202112:18 PM ET
The emergence of new and more infectious variants of the coronavirus has raised a troubling question: Will the current crop of COVID-19 vaccine prevent these variants from causing disease?
A study out Wednesday in the journal Nature suggests the answer is yes.
The research was fairly straightforward. Scientists took blood from volunteers who had received the Johnson & Johnson COVID-19 vaccine and looked at the levels of neutralizing antibodies, the kind that prevent a virus from entering cells.
"What we showed is that the neutralizing antibodies are reduced about fivefold to the B.1.351 variant," says Dan Barouch, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center in Boston. Under the new nomenclature proposed by the World Health Organization, B.1.351 is now called Beta. It first appeared in South Africa.
"That's very similar to what other investigators have shown with other vaccines," he says. "But what we also showed is that there's many other types of immune responses other than neutralizing antibodies, including binding antibodies, FC functional antibodies and T-cell responses."
And it's that last immune response, the T-cell response, that Barouch says is critically important. Because T cells, particularly CD8 T cells, play a crucial role in preventing illness.
"Those are the killer T cells," Barouch says. "Those are the types of T cells that can basically seek out and destroy cells that are infected and help clear infection directly."
They don't prevent infection; they help keep an infection from spreading.
"The T-cell responses actually are not reduced - at all - to the variants," Barouch says. It's not just the Beta variant, but also the Alpha and Gamma variants.
That may help explain why the Johnson & Johnson vaccine prevented serious disease when tested in volunteers South Africa, where worrisome variants are circulating.
"The data is very solid," says Alessandro Sette, an immunologist at the La Jolla Institute for Immunology. "Dan Barouch's data really show very nicely that there is no appreciable decrease in [CD8 T-cell] reactivity."
Sette's lab has had similar results with the Pfizer-BioNTech and Moderna COVID-19 vaccines. So has Marcela Maus at Massachusetts General Hospital. Although it will take studies in people to be certain the vaccines will work against variants, "Anything that generates a T-cell immune response to the SARS-CoV-2, I would say has promise as being potentially protective," Maus says.
What's not clear yet is how long the T-cell response will last, but several labs are working to answer that question.
---------------------
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
Nature - 09 June 2021
Abstract
The Ad26.COV2.S vaccine1–3 has demonstrated clinical efficacy against symptomatic COVID-19, including against the B.1.351 variant that is partially resistant to neutralizing antibodies1. However, the immunogenicity of this vaccine in humans against SARS-CoV-2 variants of concern remains unclear. Here we report humoral and cellular immune responses from 20 Ad26.COV2.S vaccinated individuals from the COV1001 phase 1/2 clinical trial2 against the original SARS-CoV-2 strain WA1/2020 as well as against the B.1.1.7, CAL.20C, P.1., and B.1.351 variants of concern. Ad26.COV2.S induced median pseudovirus neutralizing antibody titers that were 5.0- and 3.3-fold lower against the B.1.351 and P.1 variants, respectively, as compared with WA1/2020 on day 71 following vaccination. Median binding antibody titers were 2.9- and 2.7-fold lower against the B.1.351 and P.1 variants, respectively, as compared with WA1/2020. Antibody-dependent cellular phagocytosis, complement deposition, and NK cell activation responses were largely preserved against the B.1.351 variant. CD8 and CD4 T cell responses, including central and effector memory responses, were comparable among the WA1/2020, B.1.1.7, B.1.351, P.1, and CAL.20C variants. These data show that neutralizing antibody responses induced by Ad26.COV2.S were reduced against the B.1.351 and P.1 variants, but functional non-neutralizing antibody responses and T cell responses were largely preserved against SARS-CoV-2 variants. These findings have implications for vaccine protection against SARS-CoV-2 variants of concern.
|
|
| |
| |
|
|
|
